IL-24通过抑制PERK-eIF2α信号通路改善了阿尔茨海默病中的认知功能障碍
Yansheng Du1, Xiaolei Zheng2, Xinyi Yue3
1Department of Ultrasound, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
International immunopharmacology
|December 18, 2025
概括
阿尔茨海默病 (AD) 涉及免疫系统的变化,减少IL-24和改变的T细胞. 增加IL-24可能为AD患者提供新的治疗策略.
科学领域:
- 神经免疫学 神经免疫学
- 免疫衰变的起源
背景情况:
- 人们越来越认识到炎症在阿尔茨海默病 (AD) 中的作用.
- 周围适应性免疫细胞和IL-24对记忆力轻度认知障碍 (aMCI) 和AD的特定影响需要进一步阐明.
研究的目的:
- 在aMCI/AD.中调查周边适应性免疫细胞和IL-24表达的变化.
- 探索IL-24在AD中的治疗潜力.
主要方法:
- 在AD患者,aMCI患者和对照患者中分析T细胞子集 (CD4+中央记忆T细胞[TCM]和功效记忆T细胞[TEM]).
- 评估CD4+T细胞增殖和IL-24,IFN-γ和TNF-α的分泌.
- 在体内和体外研究评估IL-24过度表达对AD病理学的影响.
主要成果:
- 与aMCI和对照组相比,AD患者的TCM减少,TEM增加.
- 来自AD患者的CD4+T细胞表现出增加的增殖,减少IL-24和增加的IFN-γ和TNF-α分泌.
- 降低IL-24表达与阿兹海默症患者的认知功能正相关.
- 在AD模型中,IL-24过度表达改善了认知缺陷,神经病理损伤和细胞毒性.
- 这些效应可能通过抑制PERK-eIF2α通路来调解.
结论:
- 在AD中观察到向适应性免疫系统衰老的转变.
- 减少IL-24表达是AD病变发生的一个关键特征.
- IL-24代表了阿尔茨海默病的新型治疗标和策略.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
496
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
496
01:22Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K